What are the strengths, gaps, expectations, and barriers to research engagement in clinical trials as communicated through social media? Clinical trials test treatments to provide reliable information for safety and effectiveness. Trials are building blocks in which what is learned in earlier research can be used to improve treatments, compare alternatives, and improve quality of life. For 20 years, the percentages of clinical trials volunteers have decreased whereas the costs of running clinical trials have multiplied. Participants enroll in trials to access latest treatments, to help others, and to advance science, but there is growing unrest. The priorities of those running the trials differ from those of the participants, and the roles for public research involvement lack clarity. Changes to bridge these gaps in the research culture are proposed through the use of participatory action research (PAR) in which stakeholders collaborate to improve research methodology, galvanize citizen participation, multiply health knowledge, problem-solve barriers to access, and explore the value of research volunteers as collaborators. PAR enabled the inclusion of citizens as full collaborators.
| INTRODUCTION
The clinical trials field is facing unprecedented challenges even as the curative potential for medicine and health science multiplies. For more than a decade, aggressive marketing has not worked to increase the recruitment or retention 1 of participants. In the UK, 45% of trials apply for extensions to recruit participants and yet 55% of trials still fail to reach the required sample size. 2 In the last decade, 21% fewer people enroll in trials and retention rates have plummeted by 30% in the US. This is in stark contrast to the 58% increase in participant eligibility and the 3-fold increase in clinical trials registered at clinical trials.gov from 2001 to 2014. 1 Canadians report a similar decline in cancer trials coupled with mounting costs and an increase of 50 to 150 days to trial activation. data sources included clinical trials, research participants, patient preference, shared decision making, and public and patient involvement.
The data used for exploration and analysis included summarized findings from the body of narrative interview studies on clinical trials by the Health Experiences Research Group at the University of Oxford, illustrated by video, audio, and written extracts from the interviews published on healthtalk.org. 15 Snowball techniques were employed to expand the pool of relevant information until a saturation point was reached. 16 
| The research team
The research team consisted of 3 graduate research authors and 3 volunteer citizen collaborators. Everyone contributed equally to the work using a PAR framework. The volunteer citizen collaborators were trained to code and to use NVIVO software over weeks in multiple 3-hour sessions using pilot sample data.
| The coding process
After the data collection but before coding, all identifiers pertaining to organizations or individuals were removed. The data sources were randomized before the analysis to minimize bias and as a safeguard against a disproportionate amount of material from any one source.
Data were organized according to Strengths Weaknesses, Opportunities and Threats, a framework that has been used in qualitative health research. [17] [18] [19] [20] This framework helped coders to better organize the data and develop themes. NVIVO software was used to code the data with each entry independently coded by 2 researchers. 21 Discussion about coding, analysis, and authoring took place via personal contact, SKYPE, e-mail, and telephone.
| RESULTS
The results for data coding and analysis are outlined using a SWOT framework 22 with the main categories as described under the headings of Strengths, Weaknesses, Opportunities and Threats ( Figure 1 ).
The parent themes reserved for organizing the discussion were Strength through the lens of support and rewards; Weakness was linked to disparity and shame; Opportunities related the need for information and communication; Threats encompassed the themes of intimidation and loss.
| Strengths
The 2 main themes to emerge in Strengths were supportive and rewarding. The respondents described positive experiences. Respondents welcomed research feedback, new information on managing conditions, and positive reinforcement. Peer-to-peer support provided via online chats and forums was considered helpful but contact information available only for troubleshooting emergencies was not. The support and interaction were not expectations of the participants. "They gave two different lots of information. One for 'J' , the book was 'J's' to read, which was designed really for the children to read and look at. And then they gave the adults other information, which went into it in more depth really. So we were both informed of the same things but in different ways really." [healthtalk.org]
Rewards provided by trial participation went beyond the compensation provided by taking part. Rather, participants spoke about the satisfaction of taking part, that they enjoyed hoping with others that the intervention was successful and how they felt they were accessing the best available care.
"So, you know, the whole thing was a new, new experiment, but it was all done with using drugs that had been used at least, you know, for some time. So I was always quite happy. I always felt I was in good hands and never really worried at all, you know." 
| Weaknesses
The themes that contributed to weakness in the trial were those that triggered a sense of disparity and shame. Respondents were frustrated with the disparity between themselves and other stakeholders. Participants felt like objects mined for selective information if they were the "right" package. They imply that human needs for validation, respect, and care were unmet and they contrasted this with sponsors who enjoyed a voice, profits, and prestige.
"Health disparities will persist until intent and methods
and practice change." [PCORI Twitter-chat]
"Crowd-source to define the exclusion characteristics common in our specific disease; listen and learn. The goal is to allow participants to answer only a few questions, but with those questions to eliminate a majority of trials for which they fail to meet eligibility criteria." [Twitter-chat via Symplur]
"While they get a paycheck to live, we are paying with our lives" As 1 volunteer aptly stated, "Sponsors are making an investment from which they expect a return and staff is paid to make a living, their risk is small compared to ours, we gamble with our lives." [LinkedIn]
The trials participants expressed fear, desperation, shame, and inner pain. The sense of exclusion and frustration was clearly communicated. The participants shared how shame and fear heightened their sense of exclusion and disparity. They felt responsible for the trial and feared that reporting an adverse event might cause the trial to be closed down. In their minds, this destroyed the hope of a "cure"
for others. Many admit they were ashamed to ask for help when they could not understand the directions. Others say they dropped out of a trial because they lacked the funds to continue. It was common for participants to fear being labeled as difficult, blacklisted, and banned from further trials. When asked on Twitter why participants don't report serious adverse events during trials, the responses were "I'm afraid of getting kicked out."
"Too sick to know what is a side effect and what is dying."
"We were told it will ruin it for others if we say anything."
Our doctors will be mad because they would lose "the recruitment reimbursement monies" and they will drop us as patients."
"If we withdraw from the trial, we have to pay for medical treatment to fix it ourselves or sue and we do not have the money."
| Opportunities
The major themes were information and communication. 
| Threats
The themes were intimidation and loss. Participants were alarmed and angry that consequences for those that harmed them were non-existent. They wanted accountability from trial sponsors and investigators. Many participants state they were enrolled in trials by doctors but were treated only as participants and not cared for as patients.
One participant stated, "I anonymously shared the terms of the contract they photographed on the Internet only to be tracked by the sponsor through an IP number and threatened." (LinkedIn)
"When I tried to report my problems to the FDA, it was way too complicated and when I finally got someone on the phone from there, they made me feel stupid and like
I was the criminal." [LinkedIn]
Participants wanted to know about adverse events or bad outcomes. They expressed concern that trials staff were not adequately The identification of themes in weaknesses and threats can prepare researchers to consider these elements in their methodology.
The themes of disparity and loss show that experiences of rejection and exclusion are magnified through inadequate trials management.
Participants were emphatic about the need to make inclusion and exclusion criteria clear to prevent such negative experiences. Similarly, other studies report that participants deal with significant financial loss and a sense of rejection when they are excluded from trials; adding that those who are excluded are less likely to participate in another clinical trial.
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Particularly shocking was the multi-faceted expressions of shame, intimidation and the fear of reporting adverse events, which was also confirmed in other research. 26 These disparities represent clear violations of the rights of the participants. 27 If these weaknesses and threats are not curbed, participation rates will continue to decrease.
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Ethics committees would do well to consider these weaknesses and threats as violations of a participant's rights, and stop the trials in which these violations are occurring. These concerns were shared in the US congress and the National Institutes of Health grand rounds events by 1 of our volunteer content contributors. 28 Despite the challenges, strengths were apparent; the themes supportive and rewarding participants report inclusion, support, and feeling rewarded. This is in synchrony with research in which patients regularly share knowledge and contribute to empowerment in clinical trials through the healthtalk.org website. 15 Here, researchers serve as facilitators whereas patient interviews offer information and support.
Healthtalk.org are recipients of multiple British Medical Association awards indicating that their positive influence spans disciplines and social groups. 
| Recommendations
The authors considered recommendations for change in 4 areas: (1) reusable demographic trials data, (2) managing adverse effects, (3) participant profit sharing, and (4) self-recruited online participatory clinical trials.
As only 35% of excluded persons will go on to find another clinical trial for which they are a better fit, a registry to match participants to trials may reduce the rejection of participants. This, along with improved trial management in areas such as enrolment, consent, and adverse events, can lead to better participant experience. Profit sharing for participants is an issue that should also be considered in the principle of fair compensation, although ethical problems such as undue influence, can arise from this.
True participation of citizen collaborators may be the way forward.
Engaging the public in all aspects of research inclusive of trial design may well improve the quality of trials, lead to greater transparency, and generate practical insights for clinical trials. we learned that it is important to pilot the process with the same population that will be involved in research, and that technical piloting with topic experts is not sufficient.
| Limitations of the population sample
Social media and online commentary was used to capture the voice of issues that are widespread across clinical trials as expressed through online communications between patients and research participants.
The search was not limited by severity of condition, size of a trial, or common populations. Using this approach allows explorations of common experience in clinical trials across cultures, interventions, and operations. The goal of this research was not to compare experiences of interventional versus observational research or to stratify for issues of engagement related to disease, prognosis, or treatment burden. It is expected that these qualities will differ across trials and our aim was to explore common participant experience across trials. Social media collection allowed the research team to explore publicly available data that could be shared with our citizen researchers without incurring excessive costs or the data protection complications that would arise if we used clinic, hospital, or national health service records. 31 We acknowledge that the findings may exclude research participants who do not use the Internet to communicate health or research information. However, exploring a broad overview of experience through online communications can expose areas worthy of future targeted intervention for public health research and online trials.
| CONCLUSIONS
Trial participants' communications ranged from praise about support and acknowledgement about the sense of fulfillment trial participation brought them to the reality of facing disparities and loss that violated their rights. The PAR framework provided a safe space without power imbalances in which professional researchers and citizen volunteers could work as equals rather than as researcher and objects of
